Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iNeo-Vac-R01 in advanced digestive system neoplasms
NCT06019702Phase 1Recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Sep 2023
- Primary completion
- Aug 2027
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iNeo-Vac-R01 in digestive system neoplasms, sponsored by Sir Run-Run Shaw Hospital. Primary endpoints: Number of Participants with Adverse Events, Proportion of Subjects Receiving iNeo-Vac-R01 Injection Treatment to Enrolled Subjects and 1 more. Started Sep 2023; status: recruiting.
02
Drugs
iNeo-Vac-R01
03
Conditions
digestive system neoplasms
Beyond the preview
Go deeper on NCT06019702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06019702.